# US 2024/0182564 A1 · Treating cancer by blocking the interaction of tim-3 and its ligand

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0182564 A1
- Document ID: US20240182564A1
- Status: Published application
- Kind: A1
- Application number: 18/354,611
- Filed: 2023-07-18
- Published: 2024-06-06
- Earliest claimed: 2017-07-25
- Assignees: TrueBinding, Inc.
- Applicants: Truebinding, Inc.
- Inventors: Dongxu Sun; Yan Wang
- Web page: https://patentgrep.com/patent/US20240182564A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- G01N 33/505: {involving T-cells}
- G01N 33/575: for cancer
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2500/10: involving cells
- G01N 2500/20: cell-free systems
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods of activating immune response and/or treating cancer in a patient comprising administering to the patient a Gal3:TIM-3 inhibitor that interferes with the interaction between Gal3 and TIM-3, where said inhibitor is administered in an amount sufficient to activate immune response. Also provided are a humanized anti-Gal3 antibodies that can block the interaction between Gal3 and TIM3 and methods of using the anti-Gal3 antibody to treat cancer. Methods for determining if a patient's cancer is suitable for treatment with a Gal3:TIM-3 inhibitor and methods for selecting compounds that can block interaction between Gal3 and TIM-3, activating immune response and/or treating cancer are also provided.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method for determining if a cancer of a patient is suitable for treatment with a Gal3:TIM-3 inhibitor, said method comprising:
combining cells obtained from a tumor microenvironment of a known type of cancer in a patient with an antibody specific for the Gal3;
determining the level of Gal3 on the cells;
comparing the level of Gal3 on the surface of the cells with a first threshold activity value of Gal3; and
determining the cancer of the patient as suitable for treatment with a Gal3:TIM-3 inhibitor if the level of Gal3 on the surface of the cells is higher than the first threshold activity value.

### Claim 20 (depends on 19)

The method of claim 19, wherein the first threshold activity value of Gal3 is derived from a cohort of at least 100 test individuals with the same type of cancer as the patient.

### Claim 21 (depends on 20)

The method of claim 20, wherein the determining the patient's cancer as suitable for treatment step further comprises determining if the level of Gal3 on the surface of the cells obtained from the tumor microenvironment is 25% or greater as compared to a second threshold activity value of Gal3, wherein the second threshold activity value is derived from samples comprising corresponding cells from healthy patients.

### Claim 22 (depends on 19)

The method of claim 19, wherein the cells obtained from the tumor microenvironment comprises at least cancer cells and/or tumor-associated macrophages.

### Claim 23 (depends on 21)

The method of claim 21, wherein the determining the patient's cancer as suitable for treatment step further comprises determining if the level of Gal3 on the surface of the cells obtained from a tumor microenvironment is 75% or greater as compared to the second threshold activity value.

### Claim at position 7

24-39. (canceled)

### Claim 40 (depends on 19)

The method of claim 19, wherein the Gal3:TIM-3 inhibitor is an antibody comprising:
(1) a light chain variable region comprising a complementary determining region (CDR) L1, a CDR L2, and a CDR L3 and
(2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein:
the CDR L1 comprises the amino acid sequence of SEQ ID NO:17,
the CDR L2 comprises the amino acid sequence of SEQ ID NO:18,
the CDR L3 comprises the amino acid sequence of SEQ ID NO:19,
the CDR H1 comprises the amino acid sequence of SEQ ID NO:9,
the CDR H2 comprises the amino acid of SEQ ID NO: 10, and
the CDR H3 comprises the amino acid sequence of SEQ ID NO:11.

### Claim 41 (depends on 40)

The method of claim 40, wherein the heavy chain variable region has a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 25.

### Claim 42 (depends on 40)

The method of claim 40, wherein the light chain variable region has a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 26.

### Claim 43 (depends on 41)

The method of claim 41, wherein the light chain variable region has a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 26.

### Claim 44 (depends on 20)

The method of claim 20, wherein the cells obtained from the tumor microenvironment comprises at least cancer cells and/or tumor-associated macrophages.

### Claim 45 (depends on 21)

The method of claim 21, wherein the cells obtained from the tumor microenvironment comprises at least cancer cells and/or tumor-associated macrophages.
